PBC Health · Source-check · August 15, 2026

McGill Medicines ivermectin cancer dosing chart: why the horse-paste “protocol” outruns the evidence

The post is real. It combines a horse-paste ivermectin cancer/prevention chart with a William Makis video about Parkinson’s and Alzheimer’s anecdotes. The evidence does not support treating it as a public cancer protocol.

Not medical advice: Do not use veterinary ivermectin products on yourself. Do not start, stop, delay or replace cancer screening, biopsy, pathology, imaging, surgery, chemotherapy, radiation, immunotherapy, endocrine therapy, palliative care, neurology care, dementia evaluation or prescribed medication because of an X post or dosing meme.

Short answer

There is a real research kernel: ivermectin has published lab/animal anticancer mechanisms and early/limited human-interest literature. But the posted chart goes far beyond that evidence. It presents cancer-prevention/remission categories and horse-paste imagery as if a public mg/kg/day schedule is established medicine. It is not.

The article intentionally does not reprint the chart as a usable dosing schedule. The source package preserves the post for audit purposes; it is not a protocol.

Claim table

Claim	Finding
The X post/video was real and promoted an ivermectin cancer/prevention schedule.	Confirmed social-source claim.
The chart includes horse-paste / equine ivermectin imagery for human cancer-related use.	Confirmed from saved thumbnail/frames; the product image says “For Oral Use in Horses Only.”
Ivermectin has anticancer mechanisms in lab/animal literature.	Real research kernel / preclinical signal.
The chart is a proven cancer treatment or prevention regimen.	Not established; unsupported treatment/protocol leap.
Large public mg/kg/day cancer dosing tiers are medically established.	Not established; not an approved oncology regimen.
The post’s anecdotes prove cancer remission/removal.	Anecdote/testimony; not verified as controlled clinical evidence.
No long-term side effects are reported / high-dose use is essentially safe.	Misleading safety framing. FDA/DailyMed and toxicity literature warn about large doses, animal products, interactions and neurologic toxicity.
Makis video proves Parkinson’s/Alzheimer’s reversal.	Anecdotal claim. PubMed trail shows preclinical Parkinson/pathway signals, not proven human reversal; Alzheimer’s claim not verified as clinical evidence here.
Use horse paste or the posted conversion schedule.	Do not use. This article is not medical advice and does not reproduce the schedule as instructions.

What the video actually says

The downloaded video is about William Makis discussing claimed ivermectin effects in neurological conditions. The transcript includes anecdotes about Parkinson’s and Alzheimer’s, statements such as high-dose ivermectin, “just try it,” and “safe, zero risk.” Those are testimonials and claims, not controlled human evidence of disease reversal.

What the medical sources show

DailyMed/FDA label: human ivermectin tablets are indicated for intestinal strongyloidiasis and onchocerciasis, not cancer.
FDA consumer warning: animal ivermectin products are different formulations; safety in humans is not known; never use medications intended for animals on yourself or other people; large doses can be dangerous.
Oncology reviews: preclinical studies show possible anticancer mechanisms, but human clinical evidence remains limited and no large definitive randomized oncology trial confirms benefit.
Gynecologic oncology caution: the reviewed source says data are lacking, clinical studies are limited, safety/efficacy has not been assessed for treatment, and it cautions against use for gynecologic cancers.
Toxicity literature: supratherapeutic ivermectin exposure can include neurologic effects such as confusion, ataxia, altered mental status, tremor, seizures or coma in overdose/toxicity contexts.

The key correction

“Studies exist” is not the same as “this public horse-paste cancer chart is proven.” A drug can have intriguing mechanisms and still not be an established treatment, prevention plan or remission protocol. Cancer patients deserve rigorous trials, oncology oversight and pharmacy safety review — not conversion charts from social media.

Safer question to ask a clinician: “I saw ivermectin discussed online for cancer or neurological disease. Is there any clinical-trial evidence for my condition, and could it interact with my current treatment?”

Source package

Evidence label: real preclinical signal; unsupported and high-risk public dosing/protocol leap.